UPDATE: Pacira Pharma (PCRX) Tops Q3 EPS by 23c, Revenues Beat; Boosts FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results
November 1, 2018 8:00 AM EDT-- EXPAREL® net product sales of $82.2 million up 23% over prior year third quarter ---- Full-year EXPAREL net product sales guidance increased to $325 to $330 million ---- Conference Call Today at 8:30 a.m. ET --
PARSIPPANY, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the third quarter ended September 30, 2018.
As evident from these financial results, EXPAREL continues to deliver impressive sales growth with physicians having great success delivering targeted, long-acting, opioid-free local or regional analgesia for postsurgical pain in... More
